References
1. Docherty A.B., Harrison E.M., Green C.A., et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020; 369: m1985. DOI: 10.1136/bmj.m1985
2. Pimenov N.N., Komarova S.V., Karandashova I.V., Tsapkova N.N., Volchkova E.V., Chulanov V.P. Hepatitis С and its outcomes in Russia: analysis of incidence, prevalence and mortality rates before the start of the programme of infection elimination. Infektsionnye bolezni [Infectious Diseases]. 2018; 16 (3): 37–45. DOI: 10.20953/1729 9225-2018-3-37-45 (in Russian)
3. WHO Global health sector strategy on viral hepatitis 2016-2021. WHO/HIV/2016.06 http://www.who.int/hepatitis
4. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018; 69 (2): 461–511. DOI: 10.1016/j.jhep.2018.03.026
5. Recommendations for the diagnosis and treatment of adult patients with hepatitis C. Edited by V.T. Ivashkin, N.D. Yushchuk. Moscow: GEOTAR-Media, 2017. (in Russian)
6. Arasappan A., Bennett F., Bogen S.L., et al. Discovery of narlaprevir (SCH 900518): a potent, second generation HCV NS3 serine protease inhibitor. ACS Med Chem Lett. 2010; 1 (2): 64–9. DOI: 10.1021/ml9000276
7. Klimova E.A., Burnevich E.Z., Chulanov V.P., et al. Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C. Terapevticheskiy arkhiv [Therapeutic Archive]. 2019; 91 (8): 67–74. DOI: 10.26442/00403660.2019.08.000384 (in Russian)
8. Reesink H., Bergmann J., de Bruijne J., Weegink C., van Lier J., van Vliet A., et al. Safety and antiviral activity of SCH 900518 administered as monotherapy and in combination with peginterferon alfa-2b to naive and treatment-experienced HCV-1-infected patients. J Hepatol. 2009; 50: S35–S36. DOI: 10.1016/S0168-8278(09)60088-X
9. Isakov V., Koloda D., Tikhonova N., Kikalishvili T., Krasavina E., Lekishvili K., et al. Pharmacokinetics of the new hepatitis C virus NS3 protease inhibitor narlaprevir following single-dose use with or without ritonavir in patients with liver cirrhosis. Antimicrob Agents Chemother. 2016; 60 (12): 7098–104. DOI: 10.1128/AAC.01044-16
10. Mayevskaya M.V., Ivashkin V.T., Znoyko O.O., Klimova E.A., Abdurakhmanov D.T., Bakulin I.G., et al. Efficacy and safety of the Russian protease inhibitor narlaprevir at treatment-naive and earlier treated noncirrhotic patients with the 1st genotype chronic hepatitis C (PIONEER study). Rossiiskii Zhurnal Gastroenterologii, Gepatologii, Koloproktologii [Russian Journal of Gastroenterology, Hepatology, Coloproctology]. 2017; 27 (6): 41–51. DOI: https://doi.org/10.22416/1382-4376-2017-27-6-41-51 (in Russian)
11. Klimova E.A., Znoyko O.O., Chulanov V.P., Gusev D.A., Isakov V.A., Zhdanov K.V., et al. Narlaprevir, ritonavir, and sofosbuvir in non-cirrhotic chronic hepatitis C genotype 1 infected patients. Infektsionnye bolezni: novosti, mneniya, obuchenie [Infectious Diseases: News, Opinions, Training]. 2020; 9 (1): 50–6.DOI: https://doi.org/10.33029/2305-3496-2020-9-1-50-56 (in Russian)